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Head and neck squamous cell carcinoma (HNSCC) is a devastating tumor of the upper aerodigestive tract with no signiﬁcant
change in treatment modality or improvement in survival over the last several decades. Biomarkers are important biological mole-
cules that can be utilized in tumor detection, prognosis, and as targeted therapies. There are several important biomarkers and
potentialtargetsintheforefront,includingbiomarkersoftumorigenesis,signaltransductionmolecules,proteinsinvolvedinangio-
genesis, and oncogenic viruses. The clinical applications of these biomarkers are in various states from in vitro and in vivo models,
phase II and III clinical trials, to accepted modes of treatment in patients with HNSCC. Given the potential improvement in
prognosisthatbiomarkersandtheirtargetedtherapiesmayhaveonthetreatmentofHNSCC,theirinvestigationisbothimportant
and essential.
1.Introduction
Squamouscellcarcinomaisthemostcommoncancerarising
in the head and neck with devastating eﬀects on communi-
cation, swallowing, and, most importantly, survival. Head
and neck squamous cell carcinoma (HNSCC) is an epithelial
cancer arising in the upper aerodigestive tract for which new
biomarkers and targeted therapies are needed for rapid diag-
nosis and treatment. It is a tumor occurring most commonly
in the oral cavity, oropharynx, hypopharynx, and larynx [1].
In 2000, there were 480,000 new cases of HNSCC each year
worldwide and HNSCC compromised approximately 4% of
malignant neoplasms [2, 3]. In the United States, approxi-
mately 36,000 cases are expected to occur in 2010 with an
estimated 8,000 deaths [4]. Men are at greater risk than
women with the two greatest risk factors consistently being
tobacco and alcohol use. Traditionally, the major treatment
for HNSCC has been surgical resection with postoperative
chemoradiation. This treatment modality has not signiﬁ-
cantly changed over the past 30 years with only minimal im-
provement in survival. Overall survival ranges from 70 to
85% for patients presenting with early-stage disease (stage I
and II) to 30–40% for advanced-stage disease (stages III and
IV) [5]. Thus, new biomarkers for earlier detection as well as
targeted therapies are essential.
Tumor biomarkers are a novel avenue with which one
can improve early detection of tumor, improve monitoring
and treatment, and ultimately increase disease survival. Bio-
markers are biological molecules that when measured can
correlatewiththepresenceorabsenceofprimarydiseaseand
metastasis, predict disease prognosis, or oﬀer a potential tar-
getforspeciﬁedtherapies.Adiverserangeofbiomarkertypes
exist and can be measured including changes in the host
genome, diﬀerential expression of proteins involved in proc-
esses such as angiogenesis, and the presence of viral infec-
tions.Inrecentyears,severalnewbiomarkershavebeeniden-
tiﬁedandarecurrentlybeingstudiedfortheireﬀectivenessin
HNSCC detection, prognosis, and treatment.
2. Tumor Pathogenesis
Neoplasia in the head and neck is a multistep process with
sequential mutations in genes responsible for tumor surveil-
lance. A microsatellite analysis of allelic alterations demon-
strated that with the accumulation of genetic mutations, one2 ISRN Surgery
can follow the transformation from simple squamous hyper-
plasia to severe dysplasia, and, ultimately, invasive squamous
cell carcinoma [6]. p53, a tumor suppressor gene, has been
implicatedintheearlypathogenesisofHNSCC,asitcontrols
cellgrowththroughregulationofthecell-cycleandapoptosis
[7–9]. In a study analyzing HNSCC patients with a history of
tobacco and alcohol use, Brennan et al. found a signiﬁcantly
higher proportion of patients with mutations of p53 and
other distinct sites when compared to nonsmokers and non-
drinkers [10]. p53 mutations have been found in up to 50%
of HNSCC patients and have been shown to be associated
with decreased survival [8].
In addition to p53, mutations in the retinoblastoma (Rb)
gene are involved in the pathogenesis of HNSCC. p16INK4A,a
major target of the Rb pathway, is a tumor suppressor gene;
itsfunctionisinhibitedthroughavarietyofpathwaysinclud-
ing loss of heterozygosity (LOH)of chromosome 9p21 where
it is located. LOH of 9p21 is seen in 30% of premalignant
lesions and up to 80% of malignant lesions [11]. LOH in
other locations, including LOH of chromosome 3p, has also
been associated with tumorigenesis. Lee et al. examined
mutations in eight diﬀerent HNSCC cell lines and found
that three candidate oncogenes encoded on chromosome 3p
(ALS2CL,EPHA3,andCMYA1)weremutated,implyingthat
LOH of chromosome 3p is also associated with HNSCC
[12]. An ongoing clinical trial of the tyrosine kinase inhibitor
Erlotinib and oral cancer is assessing the clinical outcomes
in patients with LOH of 9p and 3p compared to patients
with normal DNA [13]. LOH of both 3p and 9p has also
been shown to help diﬀerentiate dysplastic and hyperplastic
lesions that are likely to progress to carcinoma [11, 14, 15].
Despite the fact that p53 and Rb mutations as well as LOH at
3p and 9p are clinically relevant biomarkers of HNSCC, they
have yet to be applied in daily practice.
In addition to the p53 and Rb genes, sphingosine kinases
(SphKs) have recently emerged as molecules of interest in
HNSCC. By regulating levels of ceramide, sphingosine, and
sphingosine-1-phosphate (S1P), SphK inﬂuences cells to
enter proliferative states as opposed to apoptotic states [16–
19].SphK1,theSphKisozymemoststudiedinneoplasticdis-
eases, has been shown to be upregulated in HNSCC with
overexpression in advanced stage and recurrent tumors. Use
of small molecular inhibitors or siRNA’s targeting SphK1
has been demonstrated to sensitize cells both in in vitro and
in vivo studies to radiation [20, 21]. As a cell cycle regulator
overexpressed in HNSCC patients, SphK1 provides another
prospective avenue in the treatment of HNSCC.
3. SignalTransduction Biomarkers
One of the most well-known biomarkers in HNSCC is the
EpidermalGrowthFactorReceptor(EGFR).EFGRisarecep-
tor tyrosine kinase involved in multiple downstream signal-
ingpathwaysinﬂuencingcellgrowth,angiogenesis,andinva-
sion [22]. Downstream EGFR signaling activates the mito-
gen-activated protein kinase (MAPK) pathway as well as
the phosphatidylinositol 3-kinase (PI3-K)/protein kinase B
(Akt) pathway [23]. Activation of the MAPK pathway leads
to increased expression of antiapoptotic proteins like Bcl-x2
and inhibition of proapoptotic proteins like BAD [24]. Sig-
naling through the PI3-K/Akt pathway ultimately leads to
inhibitionofthetumorsuppressorgenep53[25].Allofthese
result in a proliferative state and inhibition of tumor sup-
pressor function.
Overexpression of EGFR in HNSCC has been associated
with poorer overall survival and recurrence, and up to 90%
of HNSCC patients express EGFR [22, 26–28]. With EGFR
overexpression implicating a poor prognosis, it was one
of the ﬁrst biomarkers targeted as a potential therapy
for HNSCC. Cetuximab, a monoclonal antibody directed
against the extracellular receptor domain of EGFR, blocks
ligand binding and subsequent downstream signaling, in ad-
dition to its role in the long-term downregulation of the re-
ceptor expression [29–33]. It has been the most successful
targeted therapy applied in HNSCC to date. In a phase III
clinical trial by Bonner et al., cetuximab in combination with
radiotherapy provided an overall survival beneﬁt of an addi-
tional20monthscomparedtoradiationalone[34,35].There
have also been several clinical trials comparing chemother-
apy alone or in combination with cetuximab. In the phase III
trial,Erbituxinﬁrst-linetreatmentofrecurrentormetastatic
head and neck cancer (EXTREME), 442 patients with re-
current or metastatic HNSCC were randomized to receive
either platinum/5-FU alone or cetuximab plus platinum/5-
FU. Results showed an increase in response rate from 20% in
the chemotherapy group to 36% in the chemotherapy plus
cetuximab group, with an overall survival increase from 7.4
months in the chemotherapy group to 10.1 months in the
chemotherapy and cetuximab group [36]. Another phase III
clinical trial from the Radiation Therapy Oncology Group
(RTOG)comparingconcurrentchemoradiationandCisplat-
in versus concurrent chemoradiation with Cisplatin and cet-
uximab in patients with stage III and IV HNSCC is pending
[13].
In addition to monoclonal antibodies targeting EGFR,
small molecule tyrosine kinase inhibitors (TKIs) are also
capable of inhibiting EGFR function. Phase I and II clinical
trials in patients with recurrent or metastatic HNSCC have
been conducted on the TKIs erlotinib and geﬁtinib. With
erlotinib, these trials show an overall survival range of six to
eight months and a response rate from 4% to 21%. With
geﬁtinib, phase I and II clinical trials have demonstrated an
overall survival ranging from six to eight months, with a res-
ponse rate of 1% to 15% [37–41]. While studies of erlotinib
and geﬁtinib have demonstrated some response in HNSCC,
results of phase III clinical trials on TKIs are still pending
[13].
4. Biomarkers of Angiogenesis
In addition to their potential as useful biomarkers in
HNSCC, markers of angiogenesis provide a therapeutic op-
portunity in HNSCC. Angiogenesis play an important role
in tumor growth and progression [42]. Without new vessel
growth, tumors are unlikely to grow beyond 3mm [43–46].
There are three families of receptor tyrosine kinases involved
in angiogenesis: the ephrins and the Eph receptors, the angi-
opoetin family, and the vascular endothelial growth factorISRN Surgery 3
(VEGF)[47].Ofthesethreereceptortyrosinekinasefamilies,
VEGF is the most extensively studied. VEGF has been shown
to be overexpressed in tumor cells compared to normal cells;
this overexpression is associated with a 1.88-fold increased
risk of death and is also associated with lymph node meta-
stasis [48–50].
There are several antiangiogenic targets currently un-
dergoing clinical trial. Tyrosine kinase inhibitors of the
VEGF receptors halt their intracellular signaling. Several of
these small molecule tyrosine kinase inhibitors, sunitinib,
sorafenib, vandetanib, semaxanib, and foretinib, are under-
going phase II clinical trials [13]. Sunitinib was studied by
Machiels et al. in a phase II clinical trial of 38 HNSCC pa-
tients in which it was given as a palliative treatment; they
achieved a disease control rate of 50%. However, due to sev-
eral complications that occurred including bleeding, skin
ulceration, and ﬁstulas, they recommended further study of
the drug to assess which patients would beneﬁt [51]. So-
rafenib’s eﬀect was studied in recurrent/metastatic HNSCC
and nasopharyngeal carcinoma with a response rate of 3.7%.
Given that it is a multikinase inhibitor, its eﬀect cannot be
attributed only to its antiangiogenic activity [52]. Semaxanib
was also studied in HNSCC as a single agent, but its use was
discontinued due to several adverse aﬀects and its diﬃculty
with administration [53]. Bevacizumab, a monoclonal anti-
body against the VEGFA ligand, has been reviewed in phase
I and II clinical trials with convincing evidence of antitumor
activity in HNSCC patients when combined with erlotinib
[54, 55]. Vandetanib, a VEGF receptor inhibitor, is one of the
drugs currently undergoing clinical trial. This drug is uni-
que in that it acts as an inhibitor of the VEGF receptor,
the EGFR receptor, and the rearranged during transfection
(RET) tyrosine kinases. In vitro, it has an inhibitory eﬀect on
HNSCC cells; however, results of phase II clinical trials are
currently under investigation [13, 56].
Another receptor tyrosine kinase of potential interest
in HNSCC is the Eph receptor family and its ligands, the
Ephrins. This group of proteins has an important role in
many physiologic processes including cell aggregation and
migration, angiogenesis, and vascular network development
[57–59]. EphB4 and its sole ligand EphrinB2 are overex-
pressed in all primary and metastatic tumors, with EphB4
overexpression correlating with advanced stage disease and
lymph node metastasis. In vivo, EphB4 has also been dem-
onstratedtoprovideasurvivaladvantagetotumorcells,and,
its inhibition has been shown to decrease the survival of the
HNSCC tumor cells. Furthermore, an analysis of HNSCC
patients and EphB4/EphrinB2 expression demonstrated that
overexpression of EphB4 and EphrinB2 was associated with
a signiﬁcantly worse overall survival [60–63]. Given that
EphB4 and EphrinB2 are overexpressed in HNSCC and that
this is associated with worse overall survival, EphB4 and
EphrinB2 are potentially useful biomarkers and may provide
another target for HNSCC treatment.
5. Oncogenic Viruses
In recent years, the human papilloma virus (HPV) and its
link with HNSCC, particularly in oropharyngeal tumors, has
been illustrated. Not only can HPV be used as a biomarker of
prognostic signiﬁcance, but also as a preventative target. Of
the several types of HPV, type 16 is most commonly associa-
ted with HNSCC [64–66]. HPV is a double-stranded DNA
virus that encodes several proteins, among which are three
oncoproteins: E5, E6, and E7 [67]. The carcinogenic eﬀect
of HPV is mainly due to oncoproteins E6 and E7. HPV E6
expression ultimately leads to disruption in function of p53
and its antitumor protective eﬀect [68]. Similarly, oncopro-
tein E7 inhibits the Rb protein and its tumor suppressor
function [69].
Using either PCR or in situ hybridization assays, HPV
status can be detected in head and neck tumors [65, 70]. The
RTOG 0129 clinical trial showed that 64% of oropharyngeal
tumors were HPV-positive and that this subset of patients
was younger, less likely to use tobacco, and had smaller tu-
mors[71].Thus,HPV-positiveHNSCCpatientshaveasigni-
ﬁcantly improved survival and treatment outcome indepen-
dentofthemodeoftreatment[72–74].Inaprospectivestudy
evaluating HNSCC patients treated with induction chemo-
therapy and radiation, patients with HPV-positive tumors
had a higher response after treatment, 84% in the HPV-posi-
tivegroupversus57%intheHPVnegativetumors.Two-year
overall survival in patients with HPV-positive tumors was
95% compared to 62% in patients who were HPV negative
[72].
HPVstatuscanbeusedasabiomarkerofimprovedprog-
nosis; however, it also has a potential application in HNSCC
management, both with preventative vaccination and as a
targeted therapy. In 2006, the HPV vaccine, Gardasil was ap-
proved by the US Food and Drug Administration and re-
commended by the Center for Disease Control (CDC) in
girls and young women to prevent cervical cancer. The vac-
cine targets HPV types 6, 11, 16, and 18. Since then, in 2009,
the CDC has also recommended the vaccine in young men
aged nine through 26 for the prevention of genital warts
and HPV-associated cancers including HNSCC [75]. In an
eﬀort to utilize HPV status as a mode of treatment, Wu et al.
have developed an HPV vaccine that enhances the T-cell im-
mune response in mice with HPV-positive tumors [76]. This
vaccine has potential as a therapeutic modality in patients
with HPV-positive tumors to further improve survival.
6.BiomarkersinSaliva
WithadvancesinthesearchforbiomarkersinHNSCC,many
researchers are interested in ﬁnding potential biomarkers in
one of the most easily accessible tissues, patients’ saliva—
mainly through the study of diﬀerential gene expression,
expression of proteins such as telomerase, and through mass
spectrometry. In a study reviewing 82 candidate genes, Sethi
et al. were able to demonstrate the diﬀerential expression of
genespresentinthesalivaofHNSCCpatientsascomparedto
controls. The expression of the genes, PMAIP1 and PTPN1,
correlated with HNSCC in 27 patients compared to 10 con-
trol patients [77]. Telomerase, a protein involved in emer-
gence from cellular senescence, has an increased degree of
activity in malignant cells. With PCR-based techniques using
oral rinses from HNSCC patients, Califano et al. was able to4 ISRN Surgery
show increased telomerase activity in the saliva of HNSCC
patients compared to controls [78]. In recent years, with ad-
vances in the ﬁeld of proteomics and mass spectrometry, one
is able to simultaneously analyze multiple proteins found in
oral rinses in an attempt to discover potential tumor bio-
markers [79]. There is a signiﬁcant interest in developing a
study model with which HNSCC can be detected in saliva,
however, one biomarker or method of detection has yet to be
applied systemically outside of the laboratory setting.
7. Discussion
With further advances in our understanding of HNSCC and
itspathogenesis,HNSCCisaseeminglyheterogeneousgroup
of tumors rather than a single type with one appropriate
treatment. With the emergence of several new biomarkers,
onecanimprovedetectionoftumor,obtainprognosticinfor-
mationandoﬀernewtreatmentsinheadandnecksquamous
cell carcinoma. As we delineate which biomarkers are over-
expressed in patients, we can oﬀer individual patients with
HNSCC-speciﬁc prognostic information, and tailor treat-
ments to patients based on the molecular proﬁle of their
tumor.
To date, few of these biomarkers are applied clinically for
prognostic information. Although in many studies the over-
expression of these biomarkers has been associated with
poorer prognosis, theyhaveyettobeapplied clinically. There
are no standardized techniques or clinical values developed
to assess the expression of these biomarkers in HNSCC tu-
mor samples. HPV status is unique among this group as it
is now routinely tested in many patients with oropharyngeal
tumors and carries with it an improved prognosis. Methods
such as protein and DNA microarray technology can be used
to assess the molecular proﬁle of a tumor and test for mul-
tiple biomarkers simultaneously [80]. Thus far, microarrays
have not been applied outside the laboratory setting in
HNSCC.
EGFR expression, and its inhibition with antibodies such
as cetuximab, presents an example of how biomarkers can be
successfully used as indicators of prognosis and as thera-
peutic targets to improve survival. VEGF is likely the next
biomarker to be targeted in HNSCC therapy in daily clinical
practice. The tumor suppressor genes p53 and Rb, and regu-
latory proteins like SphK1 and EphB4/EphrinB2 oﬀer both
prognosticvalueandameanswithwhichtodetectmalignant
cells. However, the presence of these biomarkers is not rou-
tinely tested for in the clinical laboratory and therapies tar-
geting these biomarkers have yet to be developed.
While there has been a great deal of advancement in bio-
markerdetectionandtargetedtherapiesinHNSCC,thereare
stillveryimportantaspectsofHNSCCwedonotunderstand.
In patients with HNSCC, there is an approximate 4% annual
risk of developing a second primary tumor [81]. These sec-
ond primary tumors are thought to be a result of “ﬁeld can-
cerization” [82, 83]. A future area of interest would be to
identify a biomarker of ﬁeld cancerization and develop a
target that would prevent recurrence or a second primary
tumor.
HNSCC is a tumor that carries with it a signiﬁcant mor-
bidity and a very poor prognosis, especially in advanced dis-
ease. Therefore, the development of biomarkers that can play
a role in the earlier detection of tumor cells, oﬀer prognostic
information and can be used as targeted therapies is crucial.
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